337.1 ð é«åžçç
337.1.2 Indications for Initiation
- Uremic symptoms (encephalopathy, pericarditis, bleeding, persistent nausea/vomiting, malnutrition)
- Hyperkalemia refractory to medical management
- Acidosis refractory
- Volume overload refractory to diuretics
- eGFR < 10 (some advocate)
337.1.3 Timing of Initiation
- IDEAL trial (2010): early (eGFR 10-14) vs late (5-7) â no mortality benefit
- Practice: defer until symptomatic in most
- Some advocate †10 even if asymptomatic
- Patient-centered + multidisciplinary
337.1.4 Principles
- Blood through artificial kidney (dialyzer)
- Removes solutes (urea, K, etc.) by diffusion
- Removes water by ultrafiltration (pressure gradient)
- 4-hour sessions, 3x/week (standard)
337.1.5 Setup
- Blood pump 200-500 mL/min
- Dialysate flow ~ 500-800 mL/min
- Countercurrent flow
- Various membrane types
337.1.6 Vascular Access â âFistula Firstâ + âCatheter Lastâ
Arteriovenous (AV) Fistula (Gold Standard): - Surgically created connection: radial artery + cephalic vein (radiocephalic), brachial artery + cephalic vein (brachiocephalic) - Created 3-6 months before HD start - Best long-term patency - Lower infection rate - Maturation 6-12 weeks
AV Graft: - Synthetic material (PTFE) - Used when fistula not feasible - Earlier usable (2-4 weeks) - Higher complication rate
Central Venous Catheter (CVC): - Tunneled (long-term): PermCath - Non-tunneled (acute) - Highest infection + thrombosis rates - Use only as last resort or temporary
KDOQI 2019 Vein Preservation: - Avoid PICCs, subclavian access - Preserve veins (especially non-dominant arm) - Earlier referral for fistula
337.1.7 Frequency Options
In-Center Conventional HD: - 3x/week, 4 hours - Most common
Daily HD: - 5-6x/week, 2-3 hours - Better outcomes (FHN trial) - Home or in-center
Nocturnal HD (Home): - 5-6 nights/week, 6-8 hours - Slow, gentle ultrafiltration - Better BP, electrolyte control - Lifestyle benefit
Home HD: - Independence - Multiple regimens
337.1.8 Complications
Intradialytic: - Hypotension (most common â > 20%) â volume removal, autonomic dysfunction - Cramps - Nausea, vomiting - Headache - Pruritus - Chest pain - Air embolism - Disequilibrium syndrome (especially first sessions) - Hemolysis (rare) - Allergic reactions to dialyzer
Vascular Access: - Thrombosis (most common AV access complication) - Infection (especially CVC; sepsis 10x higher with CVC vs fistula) - Stenosis - Aneurysm / pseudoaneurysm - Steal syndrome (distal ischemia) - Venous hypertension - Cardiac failure (high-output)
Long-Term: - Bone disease - Anemia - Cardiovascular (most common cause of death) - Infection - Cognitive decline
337.1.9 Specific Issues
Intradialytic Hypotension: - Reduce UF rate - Cool dialysate - Sodium modeling - Midodrine prophylactic
Cramps: - Reduce UF - Stretching - Quinine controversial
Pruritus: - Treat hyperphosphatemia - Difelikefalin (NEW, Kappa-opioid receptor agonist; FDA 2021) - Antihistamines, gabapentin
337.1.10 Principles
- Peritoneum as membrane
- Dialysate dwell in peritoneal cavity
- Diffusion + osmotic ultrafiltration (via glucose, icodextrin)
337.1.11 Catheter
- Tenckhoff catheter (most common)
- Surgically placed (laparoscopic or open)
- Tunneled subcutaneous
- Exit site care critical
337.1.12 Modalities
Continuous Ambulatory PD (CAPD): - Manual exchanges - 4-5 exchanges per day - Daytime activity
Automated PD (APD) (most common): - Cycler machine at night - Nocturnal exchanges - Daytime free or one daytime dwell
337.1.13 Solutions
- Glucose-based: 1.5%, 2.5%, 4.25%
- Icodextrin (Extraneal): for long dwells (8+ hours); maltose polymer, less glucose absorption
- Bicarbonate-based (Physioneal): biocompatible
- Amino acid-based (Nutrineal): for nutrition support
337.1.14 Complications
Peritonitis (Cardinal): - Cloudy effluent + abdominal pain - > 100 WBC/ÎŒL with > 50% neutrophils - Pathogens: S. epidermidis (most common, contamination), S. aureus, GNR, fungi (rare but severe) - Treatment: intraperitoneal antibiotics (gentamicin + cefazolin or vancomycin; tailored) - Catheter removal if fungal, refractory, severe - Prevention: aseptic technique, mupirocin prophylaxis
Exit Site / Tunnel Infection: - S. aureus most common - Erythema, drainage - Treatment: oral antibiotics; catheter exchange if refractory
Mechanical: - Catheter malfunction (constipation, kinks, omental wrapping) - Hernia (abdominal pressure) - Leak (pleural, scrotal, genital) - Hydrothorax
Metabolic: - Hyperglycemia (glucose absorption) - Weight gain - Hyperlipidemia - Hypokalemia (some)
Membrane Failure: - Long-term peritoneal damage - Ultrafiltration failure - Encapsulating peritoneal sclerosis (rare, severe)
337.1.15 Modality Choice
HD Considerations: - Easier for severely sick or non-compliant - Vascular access available - Lifestyle (in-center vs home) - Hemodynamic instability
PD Considerations: - Better preserved residual renal function (first 1-2 years) - Avoid vascular access issues - Better for cardiac issues (less hemodynamic stress) - Lifestyle flexibility - Self-care + training required - Limited by peritoneal membrane lifespan - Avoided in severe abdominal pathology
337.1.16 Patient Selection
HD Preferred If: - Inability to do PD (motor, vision, cognition) - Severe abdominal disease - Massive obesity (some) - Multiple abdominal surgeries - Personal preference
PD Preferred If: - Need cardiac stability - Travel flexibility important - Working - Severe CV / poor vasc access - Pediatric
337.1.17 Outcomes
- Similar survival
- PD: better first 1-2 years
- HD: long-term benefits in some
- Modality switching common
337.1.18 Mortality
- ~ 20-25% annual mortality (US)
- Cardiovascular leading cause
- Infection 2nd
- Cancer + others
337.1.20 Hospitalization
- Common
- Access complications, infection, CV events
- Prevention focus
337.1.20.1 𩺠åºé鿥
- HD: 3x/week 4h; AV fistula gold standard
- PD: APD (nocturnal) most common; cardinal complication = peritonitis
- IDEAL trial 2010: defer initiation until symptomatic
- Vascular access: fistula first, catheter last (KDOQI 2019)
- Intradialytic hypotension: reduce UF + cool dialysate
- PD peritonitis: cloudy effluent + abd pain; intraperitoneal antibiotics
- Difelikefalin: kappa-opioid for HD pruritus (FDA 2021)
- Mortality: 20-25%/year; CV top cause